Researchers at Scripps Research Institute have developed a new high-throughput screening technique that allows identification of potential cancer and other treatments. The technique, called fluopol-ABPP, uses fluorescence polarization to rapidly detect inhibitors for uncharacterized proteins.
Researchers at Scripps Research Institute have discovered the structure of P-glycoprotein, a protein responsible for cancer cell resistance to chemotherapy. The study provides valuable insights into how P-gp transports substances out of cells and may lead to the design of more effective drugs.
Researchers use single-molecule fluorescence resonance energy transfer to observe alpha-synuclein proteins changing shape in response to different binding partners, revealing unprecedented twists and turns. This ability could play a significant role in regulating disease-related aggregates.
A Scripps Research team discovered peptides that inhibit viral production by 68-63% and reduce viral RNA levels by sevenfold. The findings offer a promising target for the development of anti-hepatitis C virus drugs.
Scientists engineer a covalent immunization approach that provides immediate protection against diseases, overcoming traditional vaccine drawbacks such as lag time. The method uses adapter molecules to trigger universal immune reactions, potentially revolutionizing disease prevention.
The discovery of the CR6261 antibody is good news for researchers aiming to design a universal flu vaccine. The antibody has the potential to treat unvaccinated individuals infected with the flu and provides broad protection against various influenza viruses, including pandemic strains.
The new technology uses self-replicating RNA molecules to detect specific chemicals, allowing for precise measurements of drugs, toxins, and other substances. This method has the potential to revolutionize fields such as medicine, environmental monitoring, and molecular computing.
Researchers discovered that mice lacking neuregulin develop dendritic spine abnormalities and exhibit hallmarks of schizophrenia, supporting the hypothesis that glutamatergic neurons play a crucial role. The study suggests that developmental defects in brain structure may contribute to schizophrenia's onset.
Researchers at Scripps Research Institute identify a mutation in the Mbtps1 gene that increases susceptibility to inflammatory bowel disease. The study reveals how the mutated gene disrupts the unfolded protein response, leading to cellular stress and inflammation.
Researchers at Scripps Institute successfully capture the crystal structure of an intermediate viral particle, revealing a dynamic process of protein coat assembly. The study provides fresh insights into viral protein interactions and suggests potential targets for interrupting virus assembly.
Scientists at Scripps Research Institute have found that anti-oxidants in the diet can help preserve function by adding them to their diet. They also developed a novel gene therapy technique to offer an alternative option for arresting vision loss from eye diseases.
Researchers identified a specific mutation in a binding structure common to dozens of kinases, leading to severe autoimmune kidney disease in mice. The study showed that eliminating Lyn kinase activity causes B cell hyperactivity and autoimmune reactions.
The Scripps Research team has developed a new technique to screen large antibody libraries against targets, enabling the acceleration of searches for new treatments against cancer and other diseases. This breakthrough allows for efficient access to the vast potential of synthetic antibodies.
Researchers at Scripps Florida have found a novel use for the old compound α-difluoromethylornithine (DFMO) in treating high-risk neuroblastoma. The study showed that even low doses of the drug could prevent cancer in animal models.
Scripps research scientists discover that loss of HMGB2 protein causes progressive cartilage deterioration, a hallmark of osteoarthritis. The study provides a promising avenue for new treatment options and may lead to prevention or reversal of the disease.
Researchers have synthesized RNA enzymes that can replicate themselves without proteins, a breakthrough in understanding the origins of life. The system, which involves two enzymes that assemble each other, has been shown to sustain molecular information and give rise to variations through Darwinian evolution.
A computational method predicts bacterial protein interactions with remarkable accuracy, identifying critical residues that bind directly with other proteins. This breakthrough enables the development of new antibiotics targeting specific protein interactions vital to pathogenic bacteria survival.
Researchers have developed a method to create novel types of stem cells, offering opportunities for expanding research and drug discovery. The technique enables the creation of rat and human pluripotent stem cells with characteristics similar to mouse embryonic stem cells.
Researchers at Scripps Research Institute have identified a single molecule, dynamin, that forms a short collar around emerging membrane fragments and squeezes them tight to separate new vesicles. This process is crucial for cellular endocytosis and may be ubiquitous throughout the cell.
Researchers have discovered how a macromolecular machine unwinds DNA within cells, allowing genetic information to be read and used to direct protein synthesis. The structure of the RSC chromatin remodeling complex provides important insights into this critical process.
Researchers at Scripps Florida found that blocking hypocretin-1 receptors significantly decreased nicotine self-administration and motivation in rats, suggesting a potential target for developing new smoking cessation treatments. The study highlights the importance of hypocretin-1 receptors in regulating nicotine reward and motivation.
Scripps researchers develop first definitive study of 2-AG's activity after discovering MAGL-specific inhibitor JZL184, reducing pain in mice and inducing effects associated with cannabinoid receptors. This breakthrough could lead to new treatments for chronic pain, obesity, anxiety, and depression.
Researchers have identified a key chemical, bicarbonate, that signals Bacillus anthracis to become lethal, offering a potential target for new antibacterial treatments. The study builds on earlier observations of the bacterium's response to host conditions, confirming bicarbonate as the essential component for virulence gene expression.
Researchers found that immune cells known as killer T cells recruit other accessory cells to drive the disease, causing blood vessel damage. This discovery offers a new avenue for possible treatments for deadly meningitis.
Researchers have identified two small molecule compounds, BIX and BayK, that can replace conventional reprogramming genes, enabling the selective reprogramming of general cells into pluripotent stem cells. This breakthrough technology offers a more precise control over the process and has distinct advantages over genetic manipulation.
Researchers at Scripps Florida have received a $1.5 million grant to develop novel drug targets for amebiasis and giardiasis, two serious water- and food-borne illnesses caused by microscopic parasites. The goal is to create small molecule inhibitors that target specific proteases playing a critical role in parasite lifecycle.
A new antibody strategy has been developed to target gastric hormone ghrelin, which is linked to weight gain and fat storage. The study found that the antibody increased metabolic rate in fasting mice and suppressed feeding after 24-hour food deprivation.
Researchers enhance the body's ability to fight cancer by boosting killer T cells' activity and keeping them alive longer. The new approach has shown promise in treating cancer patients with fewer side effects than existing treatments.
Researchers discovered how a virus suppresses the immune system in mice, allowing it to persist and cause disease. The study's findings could lead to new treatments for immunosuppressive diseases like HIV and measles by targeting the interferon response.
The Scripps Research Institute has solved the 3-D structure of Senecavirus, a viral genus that infects solid tumors such as small cell lung cancer. The unique virus shape and RNA arrangement reveal potential binding sites to cancer cells, paving the way for improved therapeutic applications.
The study provides a detailed understanding of the human A2A adenosine receptor, shedding light on its structure and potential drug targets. The findings suggest that the receptor has varying binding pockets, yielding opportunities for receptor diversity and ligand selectivity.
Researchers have discovered how the Mre11 protein bridges diverse molecular architectures at DNA breaks, resolving paradoxes about its function. The findings offer new strategies for targeting this enzyme in cancer therapies, particularly when combined with other inhibitors of DNA repair.
The Scripps Research Institute team has identified a protein called Nrm1 that plays a crucial role in regulating the cell cycle. When DNA replication stalls, Nrm1's repression of certain genes is blocked, allowing those genes to be expressed again, which enables the production of proteins needed to correct the problem.
Researchers describe the shape of the Ebola virus spike protein bound to an immune system antibody, providing a major step forward in understanding how the deadly virus works. The structure reveals vulnerable sites that can be exploited to develop potential Ebola virus vaccines or treatments.
Gabapentin has been shown to normalize the action of brain cells altered by chronic alcohol abuse in an area known as the central amygdala. The study found that gabapentin reduced anxiety-like behaviors and decreased the strength of inhibitory synapses in dependent rats, but not in non-dependent rats.
Researchers have developed a library of over 300 antibodies effective against H5N1 avian flu, offering potential treatment for infected individuals and a step towards a universal flu vaccine. The antibodies may also enable the design of vaccines with cross-subtype neutralizing activity.
A recent study published in PLOS Pathogens found that T cell proliferation is delayed by up to three days after infection, which may provide an evolutionary safeguard against autoimmune responses. This delay allows the immune system's front-line innate response to quickly control the infection before memory cell division takes place in...
Researchers used mutations of NS5A phosphoprotein to disrupt virus particle production at an early stage of assembly, preventing infectious virus release. This finding offers a research tool and potential target for developing new anti-virals for treating hepatitis C.
The Scripps Research Institute has been awarded a $4M grant to study the effects of chronic marijuana use on cognitive function, withdrawal symptoms, and stress systems. The research center aims to develop effective treatments for marijuana addiction by pooling expertise in tissue analysis, imaging, animal models, and human clinical tr...
Scripps Research will develop a compound to treat neurodegeneration in Parkinson's disease using a classical pharmaceutical approach. The goal is to bring the potential treatment to human clinical studies, aiming to have a safe and efficacious compound with sufficient preclinical safety data.
Researchers at Scripps Research Institute have discovered the mechanism behind the bright blue glow of fluorescent monoclonal antibodies, which could lead to the development of novel biosensors. The study found that a specific charge recombination between an electron hole and stilbene creates this effect.
Researchers discovered a key connection between signaling pathways and the immune response leading to severe sepsis. Disrupting this cross-talk rescued mice from death due to sepsis, suggesting potential therapeutic intervention. The study provides new insights into sepsis syndrome and its treatment.
Researchers create devices called glycodendrons to inhibit HIV transport and stimulate immune response against the virus. The approach targets a specific carbohydrate structure on the viral surface, mimicking an antibody that protects against HIV progression.
Researchers discovered that calcium channel blockers diltiazem and verapamil can restore partial enzyme homeostasis in cell lines from patients with Gaucher disease, Ą-mannosidosis, and type IIIA mucopolysaccharidosis. This finding may lead to a new treatment option for patients with neuropathic lysosomal storage diseases.
Researchers at Scripps Research Institute identified a nonsense mutation in the Coronin-1A gene that suppresses lupus development in mice. The study suggests that this mutation and other disease-suppressing genes may play a crucial role in modulating autoimmunity.
Researchers at Scripps Research Institute uncover two new methods for correcting mistakes in protein synthesis, which could help identify underlying causes of diseases. The discovery also suggests the presence of a triple redundancy system to prevent mistranslation errors.
Researchers identified specific chemical compounds that triggered aggressive behavior in male mice, shedding light on the neurological basis of behaviors. The study focused on high molecular weight proteins, which were found to activate sensory neurons in the vomeronasal organ, mediating aggressive responses.
Researchers at Scripps Research Institute have developed two new tests that can identify lethal prion strains quickly and accurately. The tests, the Standard Scrapie Cell Assay and the Cell Panel Assay, significantly accelerate prion research by producing results in under two weeks.
A new vaccine developed by the Scripps Research Institute could block deadly staph infections by sequestering autoinducers that trigger bacterial virulence. The vaccine works by inducing antibodies that bind and neutralize these molecules, preventing the shift from harmless to virulent bacteria.
Scripps researchers created a dual-action compound that leapfrogs current efforts to develop an anthrax vaccine. The new agent protects against lethal toxin exposure after only one injection, with a potent immune response faster and stronger than any currently available vaccine.